Spätfolgen in der nachsorge von krebskranken kindern und jugendlichen

Translated title of the contribution: Detection, avoidance and treatment of late effects in the follow-up of children and adolescents with cancer

T. Langer*, H. G. Dörr, S. Bielack, H. Jürgens, U. Göbel, N. Willich, J. D. Beck

*Corresponding author for this work
5 Citations (Scopus)

Abstract

Based upon the success of anti-neoplastic treatment in pediatric oncology, the detection, treatment and avoidance of late effects and the improvement of the after-care has become increasingly important. In 1995, the Late Effects Surveillance System (LESS) in the network of the Society for Pediatric Oncology and Hematology [Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)] started to register late effects in patients treated according the therapy-optimized studies of the GPOH. More than 2,500 former Ewing-, osteo- and soft tissue sarcoma patients are currently being investigated prospectively according to the follow-up guidelines of the GPOH. The most notable late effects for cancer therapy are anthracycline-induced cardiomyopathy, hearing loss and nephrotoxicity after cisplatin, ifosfamide-induced tubulopathy, as well as developmental and other endocrinological disturbances, e.g. fertility loss and dysfunction of the thyroid. New knowledge on structured aftercare is fundamental to a vertical network between physicians in hospitals and in practices for the care of children and adolescents formerly suffering from cancer.

Translated title of the contributionDetection, avoidance and treatment of late effects in the follow-up of children and adolescents with cancer
Original languageGerman
JournalOnkologe
Volume11
Issue number10
Pages (from-to)1101-1109
Number of pages9
ISSN0947-8965
DOIs
Publication statusPublished - 10.2005

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Dive into the research topics of 'Detection, avoidance and treatment of late effects in the follow-up of children and adolescents with cancer'. Together they form a unique fingerprint.

Cite this